SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 181.46-2.4%Feb 12 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (18442)4/3/1998 8:25:00 AM
From: Henry Niman  Read Replies (1) of 32384
 
Here's more on Merger Mania:
Industry Consolidation: Wait and See

NEWTOWN, Pa.--(BW HealthWire)--April 2, 1998--Despite the recent breakdown of merger talks between Glaxo Wellcome and SmithKline Beecham, another wave of industry consolidation may be on the horizon, according to the spring 1998 issue of Scott-Levin's Pharmaceutical Quarterly.

From the creation of SmithKline Beecham in 1989 to the formation of Novartis in 1996, drug companies have long been part of a cyclical consolidation trend that arises periodically in response to market conditions. As new product pipelines dry up, earnings growth begins to slow and several blockbuster drugs go off patent, consolidation will no doubt be one strategy companies use to ensure survival in the next millennium.

Other stories covered in the current Pharmaceutical Quarterly:

-- PRILOSEC Going OTC: On the heels of a September accord to co-promote PRILOSEC, Astra Merck and Procter & Gamble agreed in December to market an over-the-counter version of the world's top-selling drug.

-- Baldness Market Getting Hairy: The December approval of PROPECIA, Merck's male pattern baldness therapy, sets the stage for a head-to-head battle with Pharmacia & Upjohn's ROGAINE in 1998.

-- REZULIN Weathers Liver Warnings: Will Warner-Lambert and co-promotion partner Sankyo follow the lead of Glaxo Wellcome in the United Kingdom and pull the oral antidiabetic REZULIN off the market. So far, despite concerns about the product's possible link to liver damage, the answer is 'no.'

Each issue of Pharmaceutical Quarterly also includes roundups of major activity by brand-name, generic, biotechnology and bioinformatic companies. For more information, contact editor Al Kilpatrick or publications coordinator Steve Shewbrooks at 215/860-0440; email@scottlevin.com.

Scott-Levin, a division of PMSI/Scott-Levin Inc., provides health care consulting, research and communications services to pharmaceutical companies worldwide.

CONTACT:

Scott-Levin, Newtown

Al Kilpatrick or Steve Shewbrooks, 215/860-0440

email@scottlevin.com

www.scottlevin.com

KEYWORD: PENNSYLVANIA

BW0126 APR 02,1998
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext